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Purpose: To determine changes in pulmonary function brought 
about by lung stereotactic body radiation therapy (SBRT).
Methods: One hundred and twenty-seven patients were treated 
with lung SBRT using 48 to 60Gy in four to ﬁve fractions on a 
prospective trial. We obtained pulmonary function tests (PFTs) 
at baseline, 6 weeks, 3 months, 6 months, 9 months, 12 months, 
and 24 months after SBRT. Group mean PFT parameter values are 
reported.
Results: At baseline forced expiratory volume in 1 second (FEV1) 
was 1.5 l (67% predicted, range: 0.4–3.4 l), corrected diffusing 
capacity for carbon monoxide was 12.2 ml/min/mmHg (50.8% pre-
dicted, range: 3.3–27.2 ml/min/mmHg), and total lung capacity was 
5.7 l (102.4% predicted, range: 3.1–9.1 l). At 12 months, there was 
decline in FEV1 (−4.1%; p = 0.01), corrected diffusing capacity for 
carbon monoxide (−5.2%; p = 0.027), forced vital capacity (−5.7%; 
p = 0.004), and total lung capacity (−3.6%; p = 0.039). Declines 
in FEV1 (−7.6%; p = 0.001) and forced vital capacity (−8.9%; 
p = 0.001) persisted at 24 months. Rates of pneumonitis were 3.1% 
and 0.8% for grades 2 and 3, respectively. There were no grade 3 
PFT toxicities at 12 months. Lower PFTs at baseline and 1 year after 
SBRT did not predict for worse overall survival.
Conclusions: As the largest cohort of patients with prospective 
follow-up PFT evaluation after lung SBRT, this supports the safety 
of SBRT in this population of predominantly medically inoperable 
patients. While statistically signiﬁcant, nearly all declines in PFTs 
would be rated as a grade 1 on the Radiation Therapy Oncology 
Group scale, demonstrating safety. PFT declines were not associated 
with worse overall survival.
Key Words: Non-small cell lung cancer, Stereotactic body radio-
therapy, Pulmonary function tests.
(J Thorac Oncol. 2015;10: 1762–1769)
Although surgical resection with a lobectomy remains the standard of care for early stage non–small-cell lung can-
cer (NSCLC), treatment of these lesions with stereotactic 
body radiotherapy (SBRT) is an increasingly attractive alter-
native for patients who are not surgical candidates.
Multiple studies have examined pulmonary function 
after lobectomy.1–4 In these prior studies, reductions have been 
observed in forced vital capacity (FVC), forced expiratory vol-
ume in 1 second (FEV1), diffusing capacity of carbon monox-
ide (DLCO), and maximum oxygen consumption (VO2max).
Harada et al.5 demonstrated that smaller reductions in 
FEV1 and FVC were possible with a segmentectomy com-
pared with a lobectomy. However, the LCSG randomized trial 
comparing limited resection with either a segmentectomy or 
wedge resection with lobectomy revealed improved local con-
trol rates with lobectomy.6
Choi and Kanarek7 prospectively evaluated changes 
in pulmonary function in lung cancer patients undergoing 
conventional fractionated radiotherapy (RT) with or without 
chemotherapy. These authors reported signiﬁcant declines in 
DLCO (27% reduction), FEV1 (19%–20% reduction), total 
lung capacity (TLC; 13% reduction) up to 12 months after 
RT. However, this was only signiﬁcant in patients with a base-
line percent predicted FEV1 greater than or equal to 50%.
We have previously reported on our institutional expe-
rience with SBRT for limited stage NSCLC and have found 
excellent local control rates at 2.5 years.8
Here, we present the changes observed in pulmonary 
function tests (PFTs) in patients treated according to our single 
institution phase II study of lung SBRT for early stage NSCLC.
PATIENTS AND METHODS
Patient Eligibility
A total of 127 patients with AJCC 7 clinical stage I 
(T1–T2 N0 M0) peripheral NSCLC or a solitary lung 
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metastasis from another primary tumor were treated with 
image-guided stereotactic lung RT using daily online volumet-
ric guidance via cone-beam computed tomography (CBCT; 
Elekta Synergy or Axesse) as part of a single institution 
Phase II clinical trial between November 2005 and July 2012. 
This research was conducted with institutional review board 
approval. Participants were either deemed inoperable second-
ary to comorbid medical illness or poor PFTs or they had 
refused surgery. All tumors were ≤5 cm in size and judged to 
be technically resectable by an experienced thoracic surgeon.
All patients underwent a comprehensive staging work 
up including a complete history and physical exam, CT scan 
of the chest and upper abdomen, 18FDG-positron emission 
tomography (PET) scan, magnetic resonance imaging brain, 
ﬁne needle aspiration or core biopsy of the lesion, routine lab-
oratory studies, and baseline PFTs. If equivocal nodal disease 
was seen on PET or CT scans, a mediastinoscopy or bronchos-
copy was performed.
Pulmonary function Tests
PFTs were obtained at baseline (within 10 weeks of 
SBRT) and subsequently at 6 weeks, 3 months, 6 months, 
9 months, 12 months, and 24 months after SBRT. Studies 
evaluated FEV1, FVC, DLCO, TLC, diffusing capacity for 
carbon monoxide divided by alveolar volume (DLCO/VA), 
and arterial blood gases. DLCO values were corrected accord-
ing to hemoglobin level. PFTs were acquired and interpreted 
according to joint American Thoracic Society and European 
Respiratory Society guidelines.9–12 Prebronchodilator values 
are reported and analyzed, for both baseline and follow-up 
time points.
Radiation Simulation/Planning
All patients underwent a virtual radiation simulation 
with immobilization in a stereotactic body frame (Elekta 
Oncology, Norcross, GA), Body Fix (Elekta Oncology), or 
alpha-cradle (KGF Enterprises, Chesterﬁeld, MI). Early in 
study accrual, respiratory tumor motion was screened using 
fluoroscopy. If tumor motion was not easily visualized or 
greater than 5 mm, a four-dimensional-CT (4D-CT; Philips 
Medical Systems, Milipitas, CA) was performed. After the 
ﬁrst several patients were enrolled, a 4D-CT and a free-breath-
ing CT were obtained for all subsequent patients.
These data were transferred to the treatment planning 
workstation (Philips Pinnacle v7.4f, Milipitas, CA), and sub-
sequently registered and fused with a treatment planning PET 
scan, typically obtained with the patient in the same immobi-
lization device. The tumor was outlined on sequential axial 
CT slices to create the gross tumor volume (GTV). Adjacent 
normal structures were also contoured. GTV was deﬁned as 
the tumor visualized on CT lung windows unionized with the 
GTV as deﬁned by PET, and GTV as deﬁned in 10 phases of 
the respiratory cycle for all cases where a 4D-CT was avail-
able, rendering a ﬁnal GTV
internal target volume
 (GTV CT + GTV 
PET + GTV phase1 + GTV phase2 + GTV phase3…GTV 
phase10 = GTV ITV). As described in a prior publication,13 
the clinical target volume consisted of the GTV ITV with a 
4 mm expansion (CTV = GTV ITV + 4 mm). The planning 
target volume (PTV) consisted of a minimum 5 mm expansion 
of the CTV in three dimensions, but depended on the extent of 
tumor motion during respiration for each patient.
A stereotactic RT plan was designed using a combina-
tion of six to nine coplanar and noncoplanar beam angles and 
a limited number of couch angles. A function of the Pinnacle 
software originally designed for intensity-modulated radio-
therapy was adapted for use as an engine to inversely opti-
mize the beam aperture and weighting. The direct machine 
parameter optimization algorithm was constrained to allow 
only a single segment per beam. Dose volume objectives 
were used to develop an inversely optimized treatment plan. 
Only the beam weight and aperture were optimized; intensity-
modulated radiotherapy was therefore not routinely employed 
although was used in select cases to meet normal tissue dose 
volume constraints, and volumetrically-modulated arc therapy 
(VMAT) was used in more recent years.
A dose of 48 Gy in four fractions (12 Gy × 4) or 60 Gy 
in ﬁve fractions (12 Gy × 5) was prescribed to the PTV edge 
(60%–90% isodose line, but typically the 80% isodose line) 
for T1 and T2 or metastatic tumors, respectively. Lung dose 
volume constraints used during planning optimization aimed 
to achieve the following goals for the lungs-GTV volume: (1) 
V20 ≤ 10% (11%–15% considered minor violation), (2) V10 
or V12.5 ≤ 15%, and (3) mean lung dose less than 10 Gy. Only 
the V20 and mean lung dose constraints were required to be 
met for study entry, however. All treatments were delivered 
using daily online CBCT-based volumetric IGRT with soft tis-
sue target registration. Decadron 4 mg orally was given 15 to 
30 minutes before each fraction. Treatment was delivered with 
a minimum of 40 hours and a maximum of 4 days between 
fractions.
Both the Radiation Therapy Oncology Group (RTOG) 
PFT toxicity scale (grade 1: 10%–25% decline; grade 2: 
>25%–50% decline; grade 3: >50%–75% decline; grade 
4: >75% decline; grade 5: death) and the National Cancer 
Institute’s Common Terminology Criteria for Adverse Events, 
version 3.0 (CTCAE v3.0) were used for grading adverse 
events.14,15
Patient characteristics, disease information, and lung 
dose volume planning parameters were included in the 
descriptive analysis. The relative changes of pulmonary func-
tion were calculated from baseline and tested by paired t test. 
Correlation was tested for tumor and treatment characteris-
tics. Overall survival (OS) was calculated from the last date 
of SBRT to the date of last follow-up or death. The likelihood 
of events was calculated by the Kaplan–Meier method. The 
statistical signiﬁcance between actuarial rates was calcu-
lated with log-rank test. Results were considered statistically 
signiﬁcant if p value less than 0.05. SPSS version 20 (IBM, 
Armonk, NY) was used for analysis.
RESULTS
A total of 127 patients were treated with lung SBRT 
between November 2005 and July 2012. The median follow-
up was 25 months (range: 1–85 months). The 1- and 3-year 
OS rates for all patients were 87% and 62%, respectively. 
The baseline patient characteristics are outlined in Table 1. 
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Fourteen patients were treated for a solitary lung metastasis. As 
the majority of these patients were considered to be medically 
inoperable, baseline pulmonary function was generally poor: 
FEV1 was 1.5 l (67% of predicted); corrected DLCO was 
12.2 ml/min/mmHg (51% of predicted); TLC was 5.7 l (102% 
of predicted). Lung dose volume planning parameters are as 
follows: mean lung dose = 5.8 Gy (range: 1.8–15.5 Gy); mean 
volume of lung receiving 20 Gy = 7.6% (range: 1.5%–22.8%), 
mean volume of lung receiving 12.5 Gy = 11.1% (range: 
2%–27.6%), mean volume of lung receiving 10 Gy = 13.4% 
(range: 2.2%–32.4%); mean volume of lung receiving 5 Gy = 
24.9% (range: 5.7%–63.4%).
Relative decline in PFTs at different time points are 
listed in Table 2. There was decline in FEV1 at 12 months 
(−4.1%; p = 0.01) and 24 months (−7.6%; p = 0.001), in cor-
rected DLCO at 9 months (−6.1%; p = 0.007) and 12 months 
(−5.2%; p = 0.027), in TLC at 12 months (−3.6%; p = 0.039), 
and in FVC at 12 months (−5.7%; p = 0.004) and 24 months 
(−5.2%; p = 0.001). A trend for decline in DLCO/VA was 
observed at 12 months (−2.3%; p = 0.076).
On subgroup analysis, the 12-month decline in FEV1 
was observed only in patients with a baseline FEV1 greater 
than or equal to 50% (−6%, p = 0.01, n = 93) compared with 
patients with a baseline FEV1 less than 50% (1.4%, p = 0.82, 
n = 30). There was a trend for decline in 12-month corrected 
DLCO in both the baseline FEV1 greater than or equal to 50% 
(−4%; p = 0.1) and baseline FEV1 less than 50% (−8.4%; 
p = 0.09) subgroups. There was a decline in corrected DLCO 
at 12 months in both the baseline-corrected DLCO greater 
than or equal to 50% (−4.4%, p = 0.078, n = 44) and baseline-
corrected DLCO less than 50% (−7.4%, p = 0.21, n = 40) 
patient groups, but these did not reach statistical signiﬁcance.
There was a signiﬁcant correlation between mean GTV 
volume and TLC reduction at 12 months (p = 0.033), but 
there were no other signiﬁcant correlations found between 
PFT decline and tumor max dimension, prescription dose, 
PTV volume, lobe treated, mean lung dose, or volume of lung 
receiving 20, 12.5, or 5 Gy (data not shown).
Rates of pneumonitis were 3.1% and 0.8% for grades 2 
and 3, respectively.
PFT toxicity as calculated by the RTOG scale is sum-
marized in Table 3. Grade 2 decline in DLCO was found in 
12% of patients at 12 and 24 months. Grade 3 declines in 
DLCO were found in 1.9%, 2.4%, and 4% of patients at 3, 
6, and 24 months, respectively. Grade 2 decline in FEV1 was 
found in 8% and 9.4% of patients at 12 and 24 months, respec-
tively. Grade 2 decline in FVC was found in 6% and 12.5% 
of patients at 12 and 24 months, respectively. There were no 
grade 3 FEV1 or FVC toxicities at any time point. The vast 
majority of all declines in pulmonary function were grade 0 
to 1 for all three endpoints. The rates of grade 0 to 1 FEV1 
decline were 95% and 92% at 6 and 12 months, respectively. 
The rates of grade 0 to 1 FVC decline were 97% and 94% 
at 6 and 12 months, respectively. Grade 0 to 1 DLCO tox-
icity was recorded in 85% and 88% of patients at 6 and 12 
months, respectively. In general, PFT decline became more 
apparent over time with the exception of DLCO where 12.2% 
of patients had a grade 2 decline at 6 months which was the 
same percentage recorded at 12 months.
Patients with baseline TLC, FVC, FEV1, and corrected 
DLCO below the group mean did not have signiﬁcantly worse 
TABLE 1. Baseline Patient Characteristics Before Stereotactic 
Body Radiotherapy (n = 127)
Characteristic Number (%)
Sex
  Male 53 (42%)
  Female 74 (58%)
Median age at diagnosis (years, range) 76.9 (48.6–93.5)
Race
  Caucasian 111 (89.5%)
  African American 13 (10.5%)
Smoking history
  Nonsmoker 10 (8.1%)
  Smoker 113 (91.9%)
Pack-years smoked (range)
  <20 25 (20.7%)
  20–40 35 (28.9%)
 >40 61 (50.4%)
Pretreatment oxygen
  Yes 24 (18.9%)
  No 103 (81.1%)
Baseline pulmonary function mean (range)
  FEV1 (l) 1.5 (0.4–3.4)
  FEV1% of predicted 67% (22%–133%)
  DLCO corrected (ml/min/mmHg) 12.2 (3.3–27.2)
  DLCO% of predicted 51% (16%–99%)
  DLCO/VA uncorrected 3.01 (1.1–5.3)
  TLC (l) 5.67 (3.1–9.1)
  TLC% of predicted 102% (61%–160%)
  FVC (l) 2.53 (0.97–5.07)
  FVC% of predicted 84% (40%–129%)
Medically operable (refused surgery) 26 (20.5%)
Medically inoperable 101 (79.5%)
Tumor stage
  T1 87 (68.5%)
  T2 26 (20.5%)
  Solitary lung metastasis 14 (11.0%)
Tumor size (mean, median, range) (cm) 2.2, 2.4, 0.7–6.4
Tumor volume (mean, median, range) (cc) 5.5, 5.2, 1.7–11.8
Tumor location
  Right upper lobe 39 (30.7%)
  Right middle lobe 7 (5.5%)
  Right lower lobe 28 (22.0%)
  Left upper lobe 30 (23.6%)
  Left lower lobe 23 (18.1%)
Chemotherapy
  Yes 20 (15.7%)
  No 107 (84.3%)
FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity for carbon 
monoxide; DLCO/VA, diffusing capacity for carbon monoxide divided by alveolar 
volume; TLC, total lung capacity; FVC, forced vital capacity.
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OS compared with patients with baseline PFTs that were equal 
to or above the mean value (Fig. 1A–D). Patients that had a 
baseline TLC lower than the mean had signiﬁcantly improved 
OS at 3 years (72.5% versus 56.1%; p = 0.003) compared with 
patients with a baseline TLC greater than the mean (Fig. 1A).
Patients with baseline percent predicted FEV1 and 
corrected DLCO below 50% did not have signiﬁcantly worse 
OS compared with patients with baseline percent predicted 
FEV1 and corrected DLCO greater than or equal to 50% 
(Fig. 2A, B).
Patients with lower 1-year post-SBRT PFT values did 
not have signiﬁcantly worse subsequent OS compared with 
patients with higher PFTs at 1 year (Fig. 3A–D). Patients that 
had a TLC lower than the mean at 1 year had signiﬁcantly 
TABLE 2. Mean Pulmonary Function Test Results for All Patients After Stereotactic Body Radiotherapy
PFT Parameter TLC FVC
FVC 
%Predicted FEV1
FEV1 
%Predicted FEV1/FVC
Corrected 
DLCO DLCO/VA
Baseline 5.67 2.53 83.56 1.51 67.0% 0.59 12.23 3.01
6 weeks 5.62 2.51 83.42 1.46 66.0% 0.59 11.95 3.02
Relative Δ from baseline 1.1% −0.3% −0.3% 1.0% 0.1% 1.6% 3.1% 0.3%
3 months 5.60 2.56 84.9 1.43 65.58% 0.57 14.18 2.92
Relative Δ from baseline −0.4% 0.5% 0.4% 2.5% 3.0% 2.2% −0.7% −2.0%
6 months 5.50 2.48 96.6 1.39 66.88% 0.59 12.26 3.07
Relative Δ from baseline −0.8% 1.4% 0% 5.7% 5.1% 4.6% −2.1% 0.5%
9 months 5.55 2.48 83.52 1.42 66.67% 0.60 11.74 2.98
Relative Δ from baseline −1.2% −2.5% −1.6% 0.3% 0.9% 3.3% −6.1%* −0.5%
12 months 5.57 2.51 84.7 1.36 63.78% 0.56 11.48 2.95
Relative Δ from baseline −3.6%* −5.7%* −4.6%* −4.1%* −3.3% 1.9% −5.2%* −2.3%
24 months 5.43 2.31 81.3 1.28 63.1% 0.57 12.77 3.36
Relative Δ from baseline −2.2% −8.9%* −5.2% −7.6%* −4.1% 1.6% −11.3% 2.4%
FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity for carbon monoxide; DLCO/VA, diffusing capacity for carbon monoxide divided by alveolar volume; TLC, 
total lung capacity; FVC, forced vital capacity; FEV1/FVC, forced expiratory volume in 1 second divided by forced vital capacity; Δ, change.
*p < 0.05.
TABLE 3. Decline in Pulmonary Function According to the Radiation Therapy Oncology Group Stereotactic Body Radiotherapy 
Pulmonary Toxicity Scale
Toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
FEV1
  6 weeks 89.5% 7.4% 3.2% 0% 0%
  3 months 84.5% 15.5% 0% 0% 0%
  6 months 79.3% 15.5% 5.2% 0% 0%
  9 months 77.8% 20.4% 1.9% 0% 0%
  12 months 66% 26% 8% 0% 0%
  24 months 62.5% 28.1% 9.4% 0% 0%
FVC
  6 weeks 89.5% 8.4% 2.1% 0% 0%
  3 months 85.9% 14.1% 0% 0% 0%
  6 months 77.6% 19% 3.4% 0% 0%
  9 months 70.4% 27.8% 1.9% 0% 0%
  12 months 64% 30% 6% 0% 0%
  24 months 68.8% 18.8% 12.5% 0% 0%
DLCO
  6 weeks 77.5% 11.3% 10% 0% 1.3%
  3 months 74.1% 16.7% 7.4% 1.9% 0%
  6 months 70.7% 14.6% 12.2% 2.4% 0%
  9 months 63.4% 29.3% 7.3% 0% 0%
  12 months 63.3% 24.5% 12.2% 0% 0%
  24 months 60% 24% 12% 4% 0%
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide.
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improved OS at 3 years (85.5% versus 73.6%; p = 0.009) after 
treatment (Fig. 3A). Patients with a FVC lower than the mean 
at 1 year also had signiﬁcantly improved OS at 3 years (87.4% 
versus 70.5%; p = 0.006) after treatment (Fig. 3B).
DISCUSSION
This study reports on patients treated with SBRT for 
peripheral primary lung tumors or solitary metastases using 
daily online CBCT-based volumetric IGRT who underwent 
A B
C D
fIGURE 1. Kaplan–Meier overall survival curves of patients with baseline pulmonary function tests above or below the mean 
predicted value. A, TLC greater (solid line) and less than (dashed line) the mean; (B) FVC greater (solid line) and less than (dashed 
line) the mean; (C) FEV1 greater (solid line) and less than (dashed line) the mean; (D) DLCO adjusted for hemoglobin greater 
(solid line) and less than (dashed line) the mean. TLC, total lung capacity; FVC, forced vital capacity; FEV1, forced expiratory 
volume in 1 second; DLCO, diffusing capacity for carbon monoxide.
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baseline and serial PFTs as part of an in-house phase II clin-
ical trial. At baseline, approximately 50% of patients had 
an FEV1 of less than 70% of predicted and a DLCO of less 
than 50%.
At a median follow-up of 25 months, there was a sig-
niﬁcant decline in TLC, FVC, FEV1, and corrected DLCO, 
although the majority of those reductions would be consid-
ered grade 0 to 1 or grade 2 on the RTOG PFT toxicity grad-
ing scale. The observed reduction in FEV1 was not apparent 
until 12 months after SBRT and continued to decline up to 
24 months after treatment. Similar to Choi et al., the 
12-month decline in FEV1 was most prominent in patients 
with a baseline-predicted FEV1 greater than or equal to 
50%.7 The decline in corrected DLCO ﬁrst became signiﬁ-
cant at 9 months and persisted up to 24 months, although 
this was not statistically signiﬁcant at 24 months. TLC ﬁrst 
showed a decline of 0.4% at 3 months and steadily declined 
to 3.6% at 12 months. Cases of greater than or equal to grade 
2 pneumonitis were rare. There was no signiﬁcant correlation 
between PFT decline and dosimetric parameters such as lung 
V20, V12.5, V5, or mean lung dose, possibly related to the 
average mean lung dose being only 5.8 Gy and average lung 
V20 being approximately 7.6%.
Neither lower baseline PFTs nor reduced PFTs at 
1 year after SBRT predicted worse OS. These trends may be 
related to correlation between higher TLC, FVC, and worse 
emphysema. It is also possible that SBRT may be therapeu-
tic for patients with signiﬁcant emphysema similar to a lung 
volume reduction surgery. An alternative explanation is that 
an individual tumor’s radiosensitivity is directly related to the 
radiosensitivity of a patient’s normal tissues. The correlation 
between patient toxicity and tumor control has been previ-
ously studied in head and neck squamous cell carcinoma with 
mixed outcomes.16,17
These results are similar to the prospective study pub-
lished by Indiana University where PFTs were also obtained 
at regular 3-month intervals after SBRT. These authors 
report that a signiﬁcant decline in DLCO was at a rate of 
1.11 ml/min/mmHg/year.18 Our rate of decline in corrected 
DLCO was 0.75 ml/min/mmHg/year. The Cleveland Clinic 
published a retrospective review of 92 patients treated at 
their institution with SBRT and had PFTs completed every 3 
months after treatment.19 In their cohort, there were no signiﬁ-
cant changes in DLCO after a median follow-up of 18 months. 
The PFT outcomes of RTOG 0236 were also recently pub-
lished.20 In this prospective trial, there was a decline in DLCO 
initially, but this lost signiﬁcance after 3 months.
Similar to the outcomes of RTOG 0236, in our cohort, 
lower baseline PFTs did not predict for poorer OS. In fact, we 
found signiﬁcant improvement in OS with lower baseline TLC 
and lower TLC and FVC at 1 year after treatment. Whether 
this is a direct reflection of TLC or FVC reductions actually 
improving survival or possibly related to lung function not 
being the primary cause of death (death possibly related to 
nonlung comorbid disease or other factors) in these patients 
is not entirely clear.
Our ﬁndings compare favorably to surgical series of 
lobectomy patients where immediate postoperative reductions 
A B
fIGURE 2. Kaplan–Meier overall survival curves of patients with baseline pulmonary function tests above or below the 50% 
predicted value. A, FEV1 greater (dashed line) and less than (solid line) the 50% predicted value; (B) DLCO adjusted for hemoglo-
bin greater (dashed line) and less than (solid line) the 50% predicted value. FEV1, forced expiratory volume in 1 second; DLCO, 
diffusing capacity for carbon monoxide.
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in FEV1 and DLCO have been reported to be 25% and 23%, 
respectively.21 Greater than 3 months after surgery, several retro-
spective series report persistent reductions in FEV1 and DLCO 
in the range of 9% to 15% and 10% to 22%, respectively.2,4,21,22 
The decline in PFTs observed in our population are similar to 
those seen in patients following wedge resection or segmentec-
tomy where reductions measured greater than 6 months after 
surgery range from 3% to 4% for FEV1 and 4% to 12% for 
DLCO.23,24 Our mean reductions in FEV1 and corrected DLCO 
at 1 year were 4% and 5%, respectively. While we have observed 
A B
C D
fIGURE 3. Kaplan–Meier overall survival curves of patients with pulmonary function tests above or below the mean predicted 
value 1 year poststereotactic body radiotherapy. A, TLC greater (solid line) and less than (dashed line) the mean; (B) FVC greater 
(solid line) and less than (dashed line) the mean; (C) FEV1 greater (solid line) and less than (dashed line) the mean; (D) DLCO 
adjusted for hemoglobin greater (solid line) and less than (dashed line) the mean. TLC, total lung capacity; FVC, forced vital 
capacity; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity for carbon monoxide.
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similar reductions in FEV1 and DLCO compared with limited 
surgery, it is important to point out the distinct mechanism of 
decline with surgery (parenchymal reduction) and the proposed 
mechanism of decline with RT (injury to type II pneumocytes 
and capillary endothelial cells) may be different.25–27
As reported here, the presumption is that SBRT is the 
cause of functional declines. However, it must be considered 
that the vast majority of these patients have severe COPD. 
Followed serially for 12 to 24 months after treatment (longer 
than surgical series), these patients will have natural declines 
in pulmonary function over time according to the natural his-
tory of their COPD. It is also important to consider variation 
in PFTs attributable to the testing procedure; however, we 
attempt to minimize this with standardized equipment, quality 
assurance, and patient instruction.9–12
In this study, we were unable to identify useful dosimet-
ric parameters to predict decline in PFTs. Prior studies have 
attempted to utilize functional respiratory imaging, predomi-
nantly SPECT, in addition to standard DVH parameters to bet-
ter predict lung toxicity.28–31 The results of these initial studies 
have been promising, and obtaining pretreatment functional 
respiratory imaging may have improved our ability to deter-
mine factors that predict PFT decline.
To summarize, in this population of medically inoper-
able patients with primary NSCLC or lung metastasis, signiﬁ-
cant declines in FEV1 (−4.1%), corrected DLCO (−5.2%), FVC 
(−5.7%), and TLC (−3.6%) were observed at a median follow-up 
of 25 months. These changes did not correlate with any examined 
dosimetric parameters including V5, V12.5, V20, or mean lung 
dose. Nearly all reductions in pulmonary function after SBRT 
were RTOG grade 1 or 2 with 8%, 6%, and 12% of patients hav-
ing grade 2 declines in FEV1, FVC, and DLCO at 1 year. Lower 
baseline and follow-up PFTs did not predict for poorer subse-
quent OS, demonstrating safety and efﬁcacy of SBRT and broad 
applicability in patients with respiratory compromise
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